Characterization and comparison of commercially available TNF receptor 2-Fc fusion protein products

References

• Jenkins N, Parekh RB, James DC. Getting the glycosylation right: implications for the biotechnology industry. Nat Biotechnol 1996; 14:975 - 81; http://dx.doi.org/10.1038/nbt0896-975; PMID: 9631034
   PubMed Web of Science ®Google Scholar
• Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nat Biotechnol 2005; 23:1073 - 8; http://dx.doi.org/10.1038/nbt0905-1073; PMID: 16151394
   PubMed Web of Science ®Google Scholar
• Beck A, Wagner-Rousset E, Bussat MC, Lokteff M, Klinguer-Hamour C, Haeuw JF, et al. Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins. Curr Pharm Biotechnol 2008; 9:482 - 501; http://dx.doi.org/10.2174/138920108786786411; PMID: 19075687
   PubMed Web of Science ®Google Scholar
• Reichert JM. Antibodies to watch in 2010. MAbs 2010; 2:84 - 100; http://dx.doi.org/10.4161/mabs.2.1.10677; PMID: 20065640
   PubMed Web of Science ®Google Scholar
• Oldham RK, Dillman RO. Monoclonal antibodies in cancer therapy: 25 years of progress. J Clin Oncol 2008; 26:1774 - 7; http://dx.doi.org/10.1200/JCO.2007.15.7438; PMID: 18398141
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Guideline on similar biological medicinal products. CHMP/437/04. 2005. www.ema.europa.eu/pdfs/human/biosimilar/043704en.pdf
   Google Scholar
• European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. EMEA/CHMP/BWP/49348/2005. 2006. http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003953.pdf
   Google Scholar
• European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. EMEA/CHMP/BMWP/42832/2005. 2006. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003920.pdf
   Google Scholar
• Gottlieb S. Biosimilars: policy, clinical, and regulatory considerations. Am J Health Syst Pharm 2008; 65:Suppl 6 S2 - 8; http://dx.doi.org/10.2146/ajhp080210; PMID: 18591712
   PubMed Web of Science ®Google Scholar
• Ahmed I, Kaspar B, Sharma U. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States. Clin Ther 2012; 34:400 - 19; http://dx.doi.org/10.1016/j.clinthera.2011.12.005; PMID: 22244050
   PubMed Web of Science ®Google Scholar
• Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 2011; 29:310 - 2; http://dx.doi.org/10.1038/nbt.1839; PMID: 21478841
   PubMed Web of Science ®Google Scholar
• Stanhope R, Sörgel F, Gravel P, Pannatier Schuetz YB, Zabransky M, Muenzberg M. Bioequivalence studies of omnitrope, the first biosimilar/rhGH follow-on protein: two comparative phase 1 randomized studies and population pharmacokinetic analysis. J Clin Pharmacol 2010; 50:1339 - 48; http://dx.doi.org/10.1177/0091270009359005; PMID: 20173088
   PubMed Web of Science ®Google Scholar
• Romer T, Saenger P, Peter F, Walczak M, Le Bouc Y, Khan-Boluki J, et al. Seven years of safety and efficacy of the recombinant human growth hormone Omnitrope in the treatment of growth hormone deficient children: results of a phase III study. Horm Res 2009; 72:359 - 69; http://dx.doi.org/10.1159/000249164; PMID: 19844125
   PubMed Web of Science ®Google Scholar
• Pavlovic M, Girardin E, Kapetanovic L, Ho K, Trouvin JH. Similar biological medicinal products containing recombinant human growth hormone: European regulation. Horm Res 2008; 69:14 - 21; http://dx.doi.org/10.1159/000111790; PMID: 18059081
   PubMed Web of Science ®Google Scholar
• Romer T, Peter F, Saenger P, Starzyk J, Koehler B, Korman E, et al. Efficacy and safety of a new ready-to-use recombinant human growth hormone solution. J Endocrinol Invest 2007; 30:578 - 89; PMID: 17848841
   PubMed Web of Science ®Google Scholar
• Peterkova V, Arslanoglu I, Bolshova-Zubkovskaya E, Romer T, Zdravkovic D, Kratzsch J, et al. A randomized, double-blind study to assess the efficacy and safety of valtropin, a biosimilar growth hormone, in children with growth hormone deficiency. Horm Res 2007; 68:288 - 93; http://dx.doi.org/10.1159/000105494; PMID: 17627092
   PubMed Web of Science ®Google Scholar
• Skrlin A, Radic I, Vuletic M, Schwinke D, Runac D, Kusalic T, et al. Comparison of the physicochemical properties of a biosimilar filgrastim with those of reference filgrastim. Biologicals 2010; 38:557 - 66; http://dx.doi.org/10.1016/j.biologicals.2010.05.002; PMID: 20637652
   PubMed Web of Science ®Google Scholar
• Waller CF, Bronchud M, Mair S, Challand R. Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial. Ann Hematol 2010; 89:927 - 33; http://dx.doi.org/10.1007/s00277-010-0961-x; PMID: 20428872
   PubMed Web of Science ®Google Scholar
• Waller CF, Bronchud M, Mair S, Challand R. Comparison of the pharmacodynamic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial. Ann Hematol 2010; 89:971 - 8; http://dx.doi.org/10.1007/s00277-010-0973-6; PMID: 20567823
   PubMed Web of Science ®Google Scholar
• Waller CF, Semiglazov VF, Tjulandin S, Bentsion D, Chan S, Challand R. A phase III randomized equivalence study of biosimilar filgrastim versus Amgen filgrastim in patients receiving myelosuppressive chemotherapy for breast cancer. Onkologie 2010; 33:504 - 11; http://dx.doi.org/10.1159/000319693; PMID: 20926897
   PubMed Web of Science ®Google Scholar
• Sörgel F, Lerch H, Lauber T. Physicochemical and biologic comparability of a biosimilar granulocyte colony-stimulating factor with its reference product. BioDrugs 2010; 24:347 - 57; http://dx.doi.org/10.2165/11585100-000000000-00000; PMID: 20873878
   PubMed Web of Science ®Google Scholar
• Gascon P, Fuhr U, Sörgel F, Kinzig-Schippers M, Makhson A, Balser S, et al. Development of a new G-CSF product based on biosimilarity assessment. Ann Oncol 2010; 21:1419 - 29; http://dx.doi.org/10.1093/annonc/mdp574; PMID: 20019087
   PubMed Web of Science ®Google Scholar
• Lubenau H, Sveikata A, Gumbrevicius G, Macijauskiene J, Fokas V, Kazlauskas S, et al. Bioequivalence of two recombinant granulocyte colony-stimulating factor products after subcutaneous injection in healthy volunteers. Int J Clin Pharmacol Ther 2009; 47:275 - 82; PMID: 19356394
   PubMed Web of Science ®Google Scholar
• Lubenau H, Bias P, Maly AK, Siegler KE, Mehltretter K. Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen: single-blind, randomized, crossover trial. BioDrugs 2009; 23:43 - 51; http://dx.doi.org/10.2165/00063030-200923010-00005; PMID: 19344191
   PubMed Web of Science ®Google Scholar
• Haag-Weber M, Vetter A, Thyroff-Friesinger U, INJ-Study Group. Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis. Clin Nephrol 2009; 72:380 - 90; PMID: 19863881
   PubMed Web of Science ®Google Scholar
• Krivoshiev S, Todorov VV, Manitius J, Czekalski S, Scigalla P, Koytchev R, Epoetin Zeta Study Group. Comparison of the therapeutic effects of epoetin zeta and epoetin alpha in the correction of renal anaemia. Curr Med Res Opin 2008; 24:1407 - 15; http://dx.doi.org/10.1185/030079908X297402; PMID: 18394266
   PubMed Web of Science ®Google Scholar
• Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R, Epoetin Zeta Study Group. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment. Curr Med Res Opin 2008; 24:625 - 37; http://dx.doi.org/10.1185/030079908X273264; PMID: 18208642
   PubMed Web of Science ®Google Scholar
• Grattendick KJ, Nakashima JM, Feng L, Giri SN, Margolin SB. Effects of three anti-TNF-α drugs: etanercept, infliximab and pirfenidone on release of TNF-α in medium and TNF-α associated with the cell in vitro. Int Immunopharmacol 2008; 8:679 - 87; http://dx.doi.org/10.1016/j.intimp.2008.01.013; PMID: 18387510
   PubMed Web of Science ®Google Scholar
• Peppel K, Crawford D, Beutler B. A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med 1991; 174:1483 - 9; http://dx.doi.org/10.1084/jem.174.6.1483; PMID: 1660525
   PubMed Web of Science ®Google Scholar
• Peppel K, Poltorak A, Melhado I, Jirik F, Beutler B. Expression of a TNF inhibitor in transgenic mice. J Immunol 1993; 151:5699 - 703; PMID: 7693816
   PubMed Web of Science ®Google Scholar
• Kolls J, Peppel K, Silva M, Beutler B. Prolonged and effective blockade of tumor necrosis factor activity through adenovirus-mediated gene transfer. Proc Natl Acad Sci U S A 1994; 91:215 - 9; http://dx.doi.org/10.1073/pnas.91.1.215; PMID: 8278368
   PubMed Web of Science ®Google Scholar
• Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008; 117:244 - 79; http://dx.doi.org/10.1016/j.pharmthera.2007.10.001; PMID: 18155297
   PubMed Web of Science ®Google Scholar
• http://www.drugbank.ca/drugs/DB00005.
   Google Scholar
• RECOMMENDED INN. List 43. WHO Drug Information 2000; 14:51
   Google Scholar
• U.S. Patent number: 5605690.
   Google Scholar
• Raju TS. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol 2008; 20:471 - 8; http://dx.doi.org/10.1016/j.coi.2008.06.007; PMID: 18606225
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Ravetch JV. The antiinflammatory activity of IgG: the intravenous IgG paradox. J Exp Med 2007; 204:11 - 5; http://dx.doi.org/10.1084/jem.20061788; PMID: 17227911
   PubMed Web of Science ®Google Scholar
• Magdelaine-Beuzelin C, Kaas Q, Wehbi V, Ohresser M, Jefferis R, Lefranc MP, et al. Structure-function relationships of the variable domains of monoclonal antibodies approved for cancer treatment. Crit Rev Oncol Hematol 2007; 64:210 - 25; http://dx.doi.org/10.1016/j.critrevonc.2007.04.011; PMID: 17624800
   PubMed Web of Science ®Google Scholar
• Walsh G, Jefferis R. Post-translational modifications in the context of therapeutic proteins. Nat Biotechnol 2006; 24:1241 - 52; http://dx.doi.org/10.1038/nbt1252; PMID: 17033665
   PubMed Web of Science ®Google Scholar
• Hancock WS. Glycosylation, who cares?. J Proteome Res 2002; 1:297; http://dx.doi.org/10.1021/pr0203363; PMID: 12645884
   PubMed Web of Science ®Google Scholar
• Jefferis R. Glycosylation of recombinant antibody therapeutics. Biotechnol Prog 2005; 21:11 - 6; http://dx.doi.org/10.1021/bp040016j; PMID: 15903235
   PubMed Web of Science ®Google Scholar
• Grattendick KJ, Nakashima JM, Feng L, Giri SN, Margolin SB. Effects of three anti-TNF-alpha drugs: etanercept, infliximab and pirfenidone on release of TNF-alpha in medium and TNF-alpha associated with the cell in vitro. Int Immunopharmacol 2008; 8:679 - 87; http://dx.doi.org/10.1016/j.intimp.2008.01.013; PMID: 18387510
   PubMed Web of Science ®Google Scholar
• Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002; 301:418 - 26; http://dx.doi.org/10.1124/jpet.301.2.418; PMID: 11961039
   PubMed Web of Science ®Google Scholar
• Reichert JM, Beck A, Iyer H. European Medicines Agency workshop on biosimilar monoclonal antibodies: July 2, 2009, London, UK. MAbs 2009; 1:394 - 416; http://dx.doi.org/10.4161/mabs.1.5.9630; PMID: 20065643
   PubMedGoogle Scholar
• Takeuchi M, Inoue N, Strickland TW, Kubota M, Wada M, Shimizu R, et al. Relationship between sugar chain structure and biological activity of recombinant human erythropoietin produced in Chinese hamster ovary cells. Proc Natl Acad Sci U S A 1989; 86:7819 - 22; http://dx.doi.org/10.1073/pnas.86.20.7819; PMID: 2813359
   PubMed Web of Science ®Google Scholar
• Xie H, Chakraborty A, Ahn J, Yu YQ, Dakshinamoorthy DP, Gilar M, et al. Rapid comparison of a candidate biosimilar to an innovator monoclonal antibody with advanced liquid chromatography and mass spectrometry technologies. MAbs 2010; 2:379 - 94; PMID: 20458189
   PubMed Web of Science ®Google Scholar
• Beck A, Sanglier-Cianférani S, Van Dorsselaer A. Biosimilar, biobetter, and next generation antibody characterization by mass spectrometry. Anal Chem 2012; 84:4637 - 46; http://dx.doi.org/10.1021/ac3002885; PMID: 22510259
   PubMed Web of Science ®Google Scholar
• Berkowitz SA, Engen JR, Mazzeo JR, Jones GB. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nat Rev Drug Discov 2012; 11:527 - 40; http://dx.doi.org/10.1038/nrd3746; PMID: 22743980
   PubMed Web of Science ®Google Scholar